GSK: FDA considers new presentation of Shingrix

(CercleFinance.com) - GSK announces that the US FDA has agreed to review the regulatory application for a pre-filled syringe of Shingrix, its recombinant shingles vaccine (RZV).


This new presentation simplifies administration by eliminating the need to reconstitute components before injection, while retaining the same composition as the current vaccine.

Shingrix has been approved since 2017 for adults aged 50 and over, and since 2021 for immunocompromised adults.


Copyright (c) 2025 CercleFinance.com. All rights reserved.